|
1
|
Lazaridis KN and Gores GJ:
Cholangiocarcinoma. Gastroenterology. 128:1655–1667. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mosconi S, Beretta GD, Labianca R, Zampino
MG, Gatta G and Heinemann V: Cholangiocarcinoma. Crit Rev Oncol
Hematol. 69:259–270. 2009. View Article : Google Scholar
|
|
3
|
Razumilava N and Gores GJ:
Cholangiocarcinoma. Lancet. 383:2168–2179. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cardinale V, Semeraro R, Torrice A, Gatto
M, Napoli C, Bragazzi MC, Gentile R and Alvaro D: Intra-hepatic and
extra-hepatic cholangiocarcinoma: New insight into epidemiology and
risk factors. World J Gastrointest Oncol. 2:407–416. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cillo C: HOX genes in human cancers.
Invasion Metastasis. 14:38–49. 1994–1995.
|
|
6
|
Quinonez SC and Innis JW: Human HOX gene
disorders. Mol Genet Metab. 111:4–15. 2014. View Article : Google Scholar
|
|
7
|
Shah N and Sukumar S: The Hox genes and
their roles in oncogenesis. Nat Rev Cancer. 10:361–371. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Carrio M, Arderiu G, Myers C and Boudreau
NJ: Homeobox D10 induces phenotypic reversion of breast tumor cells
in a three-dimensional culture model. Cancer Res. 65:7177–7185.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang YF, Li Z, Zhao XH, Zuo XM, Zhang Y,
Xiao YH, Li J and Peng ZH: MicroRNA-10b is upregulated and has an
invasive role in colorectal cancer through enhanced Rhoc
expression. Oncol Rep. 33:1275–1283. 2015.PubMed/NCBI
|
|
10
|
Vardhini NV, Rao PJ, Murthy PB and
Sudhakar G: HOXD10 expression in human breast cancer. Tumour Biol.
35:10855–10860. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang L, Chen S, Xue M, Zhong J, Wang X,
Gan L, Lam EK, Liu X, Zhang J, Zhou T, et al: Homeobox D10 gene, a
candidate tumor suppressor, is downregulated through promoter
hypermethylation and associated with gastric carcinogenesis. Mol
Med. 18:389–400. 2012.
|
|
12
|
Li Q, Ding C, Chen C, Zhang Z, Xiao H, Xie
F, Lei L, Chen Y, Mao B, Jiang M, et al: miR-224 promotion of cell
migration and invasion by targeting homeobox D 10 gene in human
hepatocellular carcinoma. J Gastroenterol Hepatol. 29:835–842.
2014. View Article : Google Scholar
|
|
13
|
Nakayama I, Shibazaki M, Yashima-Abo A,
Miura F, Sugiyama T, Masuda T and Maesawa C: Loss of HOXD10
expression induced by upregulation of miR-10b accelerates the
migration and invasion activities of ovarian cancer cells. Int J
Oncol. 43:63–71. 2013.PubMed/NCBI
|
|
14
|
Sasayama T, Nishihara M, Kondoh T, Hosoda
K and Kohmura E: MicroRNA-10b is overexpressed in malignant glioma
and associated with tumor invasive factors, uPAR and RhoC. Int J
Cancer. 125:1407–1413. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xiao H, Li H, Yu G, Xiao W, Hu J, Tang K,
Zeng J, He W, Zeng G, Ye Z, et al: MicroRNA-10b promotes migration
and invasion through KLF4 and HOXD10 in human bladder cancer. Oncol
Rep. 31:1832–1838. 2014.PubMed/NCBI
|
|
16
|
Hakami F, Darda L, Stafford P, Woll P,
Lambert DW and Hunter KD: The roles of HOXD10 in the development
and progression of head and neck squamous cell carcinoma (HNSCC).
Br J Cancer. 111:807–816. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Edge SBBD; Compton CC, Fritz AG, Greene FL
and Trotti A: AJCC Cancer Staging Manual. 7th edition. Springer;
New York: pp. 60–62. pp. 66–71. 2010
|
|
18
|
Ma L, Teruya-Feldstein J and Weinberg RA:
Tumour invasion and metastasis initiated by microRNA-10b in breast
cancer. Nature. 449:682–688. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu Z, Zhu J, Cao H, Ren H and Fang X:
miR-10b promotes cell invasion through RhoC-AKT signaling pathway
by targeting HOXD10 in gastric cancer. Int J Oncol. 40:1553–1560.
2012.PubMed/NCBI
|
|
20
|
Zhao ZH, Tian Y, Yang JP, Zhou J and Chen
KS: RhoC, vascular endothelial growth factor and microvascular
density in esophageal squamous cell carcinoma. World J
Gastroenterol. 21:905–912. 2015.PubMed/NCBI
|
|
21
|
Gou WF, Zhao Y, Lu H, Yang XF, Xiu YL,
Zhao S, Liu JM, Zhu ZT, Sun HZ, Liu YP, et al: The role of RhoC in
epithelial-to-mesenchymal transition of ovarian carcinoma cells.
BMC Cancer. 14:4772014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Iiizumi M, Bandyopadhyay S, Pai SK, Watabe
M, Hirota S, Hosobe S, Tsukada T, Miura K, Saito K, Furuta E, et
al: RhoC promotes metastasis via activation of the Pyk2 pathway in
prostate cancer. Cancer Res. 68:7613–7620. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bu Q, Tang HM, Tan J, Hu X and Wang DW:
Expression of RhoC and ROCK-1 and their effects on MAPK and Akt
proteins in prostate carcinoma. Zhonghua Zhong Liu Za Zhi.
33:202–206. 2011.In Chinese. PubMed/NCBI
|
|
24
|
Islam M, Datta J, Lang JC and Teknos TN:
Downregulation of RhoC by microRNA-138 results in de-activation of
FAK, Src and Erk1/2 signaling pathway in head and neck squamous
cell carcinoma. Oral Oncol. 50:448–456. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mathema VB and Na-Bangchang K: Current
insights on cholangiocarcinoma research: A brief review. Asian Pac
J Cancer Prev. 16:1307–1313. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ulahannan SV, Rahma OE, Duffy AG,
Makarova-Rusher OV, Kurtoglu M, Liewehr DJ, Steinberg SM and Greten
TF: Identification of active chemotherapy regimens in advanced
biliary tract carcinoma: A review of chemotherapy trials in the
past two decades. Hepat Oncol. 2:39–50. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liao CG, Kong LM, Zhou P, Yang XL, Huang
JG, Zhang HL and Lu N: miR-10b is overexpressed in hepatocellular
carcinoma and promotes cell proliferation, migration and invasion
through RhoC, uPAR and MMPs. J Transl Med. 12:2342014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Redline RW, Hudock P, MacFee M and
Patterson P: Expression of AbdB-type homeobox genes in human
tumors. Lab Invest. 71:663–670. 1994.PubMed/NCBI
|
|
29
|
Ruth MC, Xu Y, Maxwell IH, Ahn NG, Norris
DA and Shellman YG: RhoC promotes human melanoma invasion in a
PI3K/Akt-dependent pathway. J Invest Dermatol. 126:862–868. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ridley AJ: RhoA, RhoB and RhoC have
different roles in cancer cell migration. J Microsc. 251:242–249.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Oxford G and Theodorescu D: Ras
superfamily monomeric G proteins in carcinoma cell motility. Cancer
Lett. 189:117–128. 2003. View Article : Google Scholar
|
|
32
|
Karlsson R, Pedersen ED, Wang Z and
Brakebusch C: Rho GTPase function in tumorigenesis. Biochim Biophys
Acta. 1796:91–98. 2009.PubMed/NCBI
|
|
33
|
Tumur Z, Katebzadeh S, Guerra C, Bhushan
L, Alkam T and Henson BS: RhoC mediates epidermal growth
factor-stimulated migration and invasion in head and neck squamous
cell carcinoma. Neoplasia. 17:141–151. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chen R, Cheng Y, Zhang Y, Li Z and Geng L:
RhoC mediates invasion and migration of CaSki cells through the
Rho-associated serine-threonine protein kinase 1 signaling pathway.
Int J Gynecol Cancer. 24:184–191. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bellovin DI, Simpson KJ, Danilov T,
Maynard E, Rimm DL, Oettgen P and Mercurio AM: Reciprocal
regulation of RhoA and RhoC characterizes the EMT and identifies
RhoC as a prognostic marker of colon carcinoma. Oncogene.
25:6959–6967. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang W, Yang LY, Yang ZL, Peng JX and Yang
JQ: Elevated expression of autocrine motility factor receptor
correlates with overexpression of RhoC and indicates poor prognosis
in hepato-cellular carcinoma. Dig Dis Sci. 52:770–775. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Maemura K, Natsugoe S and Takao S:
Molecular mechanism of cholangiocarcinoma carcinogenesis. J
Hepatobiliary Pancreat Sci. 21:754–760. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Dokduang H, Juntana S, Techasen A, Namwat
N, Yongvanit P, Khuntikeo N, Riggins GJ and Loilome W: Survey of
activated kinase proteins reveals potential targets for
cholangiocarcinoma treatment. Tumour Biol. 34:3519–3528. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Leelawat K, Udomchaiprasertkul W, Narong S
and Leelawat S: Induction of MKP-1 prevents the cytotoxic effects
of PI3K inhibition in hilar cholangiocarcinoma cells. J Cancer Res
Clin Oncol. 136:1537–1544. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Okada T, Sawada T and Kubota K: Rapamycin
inhibits growth of cholangiocarcinoma cells.
Hepatogastroenterology. 56:6–10. 2009.PubMed/NCBI
|
|
41
|
El-Khoueiry AB, Rankin CJ, Ben-Josef E,
Lenz HJ, Gold PJ, Hamilton RD, Govindarajan R, Eng C and Blanke CD:
SWOG 0514: A phase II study of sorafenib in patients with
unresectable or metastatic gallbladder carcinoma and
cholangiocarcinoma. Invest New Drugs. 30:1646–1651. 2012.
View Article : Google Scholar :
|
|
42
|
Ma L, Reinhardt F, Pan E, Soutschek J,
Bhat B, Marcusson EG, Teruya-Feldstein J, Bell GW and Weinberg RA:
Therapeutic silencing of miR-10b inhibits metastasis in a mouse
mammary tumor model. Nat Biotechnol. 28:341–347. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhang H, Cai K, Wang J, Wang X, Cheng K,
Shi F, Jiang L, Zhang Y and Dou J: miR-7, inhibited indirectly by
lincRNA HOTAIR, directly inhibits SETDB1 and reverses the EMT of
breast cancer stem cells by downregulating the STAT3 pathway. Stem
Cells. 32:2858–2868. 2014. View Article : Google Scholar : PubMed/NCBI
|
